RenovoRx, Inc. Common Stock
Follow $RNXT
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $RNXT by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is RNXT moving today?
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
RNXT overview
Related filings and maps
Congress activity in RNXT
No receipt-qualified Congressional disclosure is present for RNXT in the cached public ledger.
RNXT contract awards, year to date.
Public federal awards linked to this ticker.
RNXT lobbying filings, year to date.
Registered lobbying filings matched to RenovoRx, Inc. Common Stock.